Biopharmaceutical Innovation

Discovery. Innovation. Collaboration.

 

The students, faculty and researchers involved in biopharmaceutical sciences at the University take an interdisciplinary approach to addressing grand challenges of healthcare, medicine and biopharmaceutical manufacturing—creating solutions from living cells. UD is innovating research, academics and workforce training in the cutting-edge field of biopharmaceuticals.

Biopharmaceutical Research

BIOPHARMACEUTICAL
RESEARCH & DEVELOPMENT

As an academic institution, the spirit of discovery is inherent at the University of Delaware. However, our students, faculty and staff are also advancing new innovations in biopharmaceutical development and manufacturing to help address the unprecedented growth and demand in this industry sector. 

More on Biopharmaceutical R&D at UD





BIOPHARMACEUTICAL SCIENCES MASTER'S PROGRAM

The newest addition to UD’s academic programs for the industry is a master’s degree in biopharmaceutical sciences. The program emphasizes hands-on learning in all technical courses, providing immersive exposure to open-ended problems as well as business, finance and regulatory constraints. In addition, students connect practical and conceptual learnings through a unique 15-month internship model that runs parallel with coursework. 

M.S. & 4+1 Program Details
 

INNOVATIVE FACILITIES 

While many spaces throughout UD’s campus are home to biopharmaceutical research, training and academics, the Ammon Pinizzotto Biopharmaceutical Innovation Center is the scientific epicenter for UD’s biopharmaceutical sciences initiative. The facility brings together academia, industry and government to create an interdisciplinary hub of discovery, innovation and industrial practice based on collaborative approaches. It is also home to NIIMBL, leveraging UD’s foundation of impactful partnerships.

STAR Campus

UNDERGRADUATE & GRADUATE PROGRAMS

Biopharma Sciences: youtube.com/watch?v=JkSWT1JjHeg

From foundational, interdisciplinary undergraduate classes to a new master’s program, UD is ensuring the next generation of biopharmaceutical sciences professionals are well trained and prepared to tackle the dynamic industry. Listed here are some of the most popular undergraduate and graduate pathways to various careers in the biopharmaceutical industry.

To learn more about how you or your company can help shape the future of biopharmaceutical sciences or partner with the University’s initiatives, contact:

Dana Raftas, Assistant Vice President of Strategic Initiatives & Lerner College, at draftas@udel.edu.

UD Biopharma News

Kelvin Lee
Headshots of NIIMBL fellows

Biopharmaceutical Innovation Advisory Board

 

The Biopharmaceutical Innovation Advisory Board consists of industry leaders, venture capitalists and academic partners who advise and assist with the growing academic interest of biopharmaceutical innovation at the University of Delaware, including discovery and manufacturing.

The board’s mission is to offer distinctive and innovative partnerships and educational opportunities related to the biopharmaceutical industry, ensuring the University remains at the forefront of the growth and progression of this industry.

 

Board Members

CAROL A. AMMON ’11H
Founder and Chief Executive Officer (Retired)
Endo Pharmaceuticals


DENNIS ASSANIS

President
University of Delaware


ELENI ASSANIS

First Lady
University of Delaware


ANDREW COTTONE, III
Founder and President
Adesis


STEPHEN K. DOBERSTEIN ’81

Chief Scientific Fellow (Retired)
Nektar Therapeutics


DAVID V. ELKINS ’91

Executive Vice President and Chief Financial Officer
Bristol-Myers Squibb

CHAITANYA R. GADDE ’06M
Chief Executive Officer
BioTek reMEDys


GREG HANNON

Chief Technical Officer
W.L. Gore and Associates, Inc.


KIRK D. MALLOY ’90M ’93PHD

Chief Executive Officer
Verogen, Inc.


MARIE E. PINIZZOTTO ’08M ’19H

Senior Director of Global Safety Surveillance and Epidemiology (Former)
Wyeth, LLC

DENNIS J. PURCELL ’77
Founder and Senior Advisor
Aisling Capital


RICHARD ROGEL

Special Representative
University of Michigan


SUSAN ROGEL

Special Representative
University of Michigan

HELEN C. STIMSON
Chief Operating Officer (Retired)
Adesis


MIKE THIEN

Senior Vice President of Global Science, Technology & Commercialization
Merck & Co. Inc.


DOUGLAS A. TRECO ’79
Co-founder, President and Chief Executive Officer
Ra Pharmaceuticals


KRIS VADDI

Founder and President
Prelude Therapeutics


TRACY VANDERSLICE
Vice President and Head of Global Clinical Sciences & Delivery
GlaxoSmithKline


NICHOLAS H. VROLIJK ’88M ’92PHD
Managing Director
BDO’s BioProcess Technology Group


GAIL WASSERMAN
Senior Vice President of Biopharmaceutical Development
AstraZeneca